Objective：To evaluate the clinical value of serum carbohydrate antigen（CA）153，CA125，carcinoembryonic antigen（CEA） combined detection in the diagnosis of breast cancer. Methods：Chemiluminescent microparticle immunoassay（CMIA） was used to detect the serum levels of CA153，CA125，CEA in 81 patients with breast cancer，55 patients with benign breast diseases and 67 healthy women. Results：The levels and positive rates of CA153，CA125 and CEA in patients with breast cancer were significantly higher than those in patients with benign breast diseases and healthy controls（P<0.05）. The positive rate of CA153（49.38%） was the highest among three tumor markers. The sensitivity，specificity，accuracy and negative predictive values of combined detection of CA153，CA125 and CEA were 69.14%，96.72%，85.71% and 82.52%，respectively. The value of specificity in combined detection was decreased slightly，while the values of other indicators were higher in combined detection than in single detection. The positive rate of CA153 was obviously lower in breast cancer patients at stage Ⅰ and Ⅱ（15.91%） than in those at stage Ⅲ and Ⅳ（89.19%）. The combined detection of CA153，CA125 and CEA greatly improved the positive rates for breast cancer patients at different clinical stages（stageⅠ and Ⅱ：47.73%，stage Ⅲ and Ⅳ：94.59%）. The area under receiver operating characteristic（ROC） curves of CA153，CA125 and CEA was 0.774，0.664 and 0.690 respectively. The area under ROC curves of the combined detection was 0.807. Con－clusions：The clinical value of single tumor marker detection in the early diagnosis of breast cancer is limited. The combined detec－tion of CA153，CA125 and CEA is beneficial to improving the diagnosis performance as well as to increasing the early diagnosis rate for breast cancer. In addition，it is helpful to the differential diagnosis between breast cancer and benign breast diseases. The combined detection of CA153，CA125 and CEA is an ideal marker combination in the detection of breast cancer.